Kornimate/medical-research-clean huggingface dataset:
a companion diagnostic study to develop circulating exosomes as predictive biomarkers for the response to immunotherapy in renal cell carcinoma

Conditions: Renal Cell Carcinoma

Summary: immune checkpoint inhibitors targeting pd-1 or pd-l1 have been developed and clinical trials showning better response in unselected patients with metastatic renal cell carcinoma (rcc). at the moment, no clear biomarker exists to accurately predict anti-pd1/pdl1 rcc responsiveness. the objective of this study is to develop and evaluate the utility of circulating exosomes as companion diagnostic biomarker for predicting response to immunotherapy in patients with rcc.


Eligibility criteria:
inclusion criteria: * advanced metastatic rcc * scheduled to initiate an immunocheckpoint inhibitors or in combination with them * age \>= 18 years * able to provide informed consent exclusion criteria: * other, unrelated, concomitant active, invasive malignancy
assessment of hematologic indices in juvenile lupus erythematosus patients:correlation with disease activity and chronic organ damage in these patients

Conditions: Juvenile Systemic Lupus Erythematosus

Summary: the study aim to evaluate the relationship between some important hematologic indices in juvenile lupus erythematosus patients and if these indices may be use as markers of disease acitivity in these patients or not ,also evaluate the relationship with these markers and chronic organ damage index

we calculate important hematologic indices in children diagnosed as sle as systemic inflamatory index ,systemic inflamatory response index and aggregate index of systemic inflamation in these patients ,and correlate these indices with sle disease activity index and chronic damage index in these patients.

Eligibility criteria:
inclusion criteria: * patients who fillful 2012 slicc criteria or 2019 acr/eular criteria of systemic lupus erythematosus * age of patients at disease onset before 18 years exclusion criteria: * adult onset disease ( age at disease onset after 18 years * any other chronic inflamatory disorders or other autoimmune diseases
verification of the safety of early discharge in patients after acute st-segment myocardial infarction

Conditions: Coronary Artery Disease; Acute Myocardial Infarction With ST-segment Elevation; Primary Percutaneous Coronary Intervention; Early Discharge

Summary: the aim of the study is to prove that early discharge (within 72 hours) in selected group of patients after myocardial infarction with elevations of st-segment is feasible and safe

the aim of the study is to prove * that early discharge (within 72 hours) in selected group of patients with low risk of follow-up complications after myocardial infarction with elevations of st-segment, treated with primary percutaneous coronary intervention, is feasible and safe * that early discharge is comparable with the group of patients, discharged in a standard way accordingly with present practice and physician´s decision (usually 4th-7th day), thus it is not associated with higher incidence of complications in 90th day after myocardial infarction

Eligibility criteria:
inclusion criteria: * signed informed consent * age ≥18 do ≤ 75 years * acute myocardial infarction with st-segment elevation, treated with successful percutaneous coronary intervention within 12 hours from the onset of symptoms * left ventricle ejection fraction ≥ 45% by echocardiography * single- or two-vessel disease (stenosis of major epicardial artery ≥ 70%) * haemodynamic and rhythmic stability (killip class i, no arrythmia requiring treatment occurring \> 2 hours after pci) * assumed good cooperation and social background exclusion criteria: * symptoms of residual ischemia * significant comorbidities or abnormalities in paraclinical tests, requiring additional evaluation within continuing hospitalization * contraindication of dual antiplatelet therapy or need for anticoagulation therapy * hihg risk of bleeding complications * participation in other clinical study

Keywords: st-segment elevation myocardial infarction primary percutaneous coronary intervention low risk early discharge
ultrasound of supraspinatus muscle tears

Conditions: Supraspinatus Tear or Rupture, Not Specified as Traumatic

Summary: the supraspinatus is a relatively small muscle of the upper back that runs from the supraspinatus fossa superior portion of the scapula to the greater tubercle of the humerus. it is one of the four rotator cuff muscles and also abducts the arm at the shoulder. a supraspinatus tear is a tear or rupture of the tendon of the supraspinatus muscle.

many pathological conditions as trauma (whether acute or chronic), inflammation or instability may cause supraspinatus muscle disease which is one of the commonest cause of shoulder pain and malfunction. supraspinatus muscle failure usually results from tendinopathy that transforms from partial to full thickness tears. basically shoulder impingement is a clinical diagnosis. the role of imaging in such condition is to identify the causal factors as well as to detect the involvement of tendon injuries and its extension as tears of the cuff muscles is difficult to be identified clinically. the decision making in the treatment of the supraspinatus muscle tears relies mainly upon the correct diagnosis of the type and extent of the tear. according to the diagnosis whether conservative or surgical treatment is chosen, even the type of the surgical intervention (open or arthroscopic) would differ according to the diagnosis. in addition identifying the extent of tendons retraction and the condition of the ruptured edges, as well as the quality of the muscle itself influences the management policy. to evaluate the painful shoulder a variety of imaging tests have been used; yet, for diagnosing a supraspinatus muscle tear the standard imaging modalities such as unenhanced magnetic resonance imaging, indirect and direct magnetic resonant arthrography, and ultrasound are used. us of the shoulder is utilized increasingly in healthcare settings to assess the integrity of the supraspinatus muscle. it is a non-invasive examination with practically no side effects. it is beneficial in the dynamic examination of the tendon during movement of the shoulder .

Eligibility criteria:
inclusion criteria: * patients of different age groups presented with clinical diagnosis department of shoulder impingement and diagnosed by magnetic resonance imaging as supraspinatus exclusion criteria: * patients with previous shoulder surgery
a multi-center study for individual treatment of helicobacter pylori infection

Conditions: Gastritis; Gastric Ulcer

Summary: since the discovery of helicobacter pylori (h. pylori), many studies have been carried out with the goal of improving h. pylori eradication and therapies have changed from single-antibiotic treatments to the current multi-antibiotic treatments. however, the eradication rate of h. pylori is still less than 80%. the reasons for this low eradication rate are likely to be multi-factorial, including the reduced activity of antimicrobial drugs, poor patient compliance or micro-environment in stomach. in this study, to obtain the higher eradication of h. pylori and discover the different mechanism between the current infection and refractory infection of h. pylori, it is necessary to perform a prevalence survey for eradication of h. pylori based on the results from isolation of h. pylori strains, antibiotic susceptibility testing, cyp2c19 gene polymorphism, drug resistance gene sequencing and 16srrna sequencing.


Eligibility criteria:
inclusion criteria: 1. age 18\~70 years old, male or female, untreated patients. 2. symptoms of abdominal pain, bloating, acid reflux, belching, nausea, vomiting, heartburn, chest pain, vomiting, melena, etc. 3. unused antibiotics, bismuth, h2 receptor antagonists or ppi by nearly 4 weeks 4. 13c-labelled urea breath test positive. 5.agreed to helicobacter pylori culture and sensitivity testing taken by endoscopy gastric biopsy specimens,and the result of culture was positive. 6.agreed to helicobacter pylori eradication therapy and cooperate with the eradication efficacy follow-up survey. exclusion criteria: 1. severe heart, liver, kidney dysfunction. 2. pregnant or lactating women. 3. complications of bleeding, perforation, pyloric obstruction, cancer. 4. esophageal,gastrointestinal surgery history. 5. patients can not properly express their complaints,such as psychosis, severe neurosis. 6. taking nsiad or alcohol abusers. 7. allergic to penicillin or either drugs of the 6 antibiotic tested by susceptibility testing.

Keywords: helicobacter pylori antibiotic resistance sequencing mechanism cause
machine learning in the icu: predicting mortality in bloodstream infections (icu:intensive care unit)

Conditions: Carbapenem Resistant Bacterial Infection

Summary: using our own patient data, our study aimed to predict mortality that can develop in carbapenem-resistant gram-negative bacilli bloodstream infections with a machine learning-based model. in the intensive care unit, patients with bloodstream infections, both with and without mortality, will be examined retrospectively in two subgroups for comparison.

carbapenems are one of the last-resort antibiotics used to treat severe infections caused by multi-drug resistant gram-negative pathogens. infections with carbapenem-resistant gram-negative bacilli (cr-gnb) have become widespread in the past decade, posing serious threats to public health. carbapenem-resistant enterobacteriaceae (cre), carbapenem-resistant acinetobacter baumannii (crab), and carbapenem-resistant pseudomonas aeruginosa (crpa) top the priority list of antibiotic-resistant bacteria worldwide. cr-gnb causes a broad spectrum of infections, including bacteremia, urinary tract infections, pneumonia, and intra-abdominal infections. carbapenem-resistant bloodstream infections are a significant cause of morbidity and mortality, and therapeutic options in treatment are extremely limited. by evaluating risk factors in patients monitored in the intensive care unit, scoring systems that can predict prognosis reduce mortality risk by ensuring the early application of effective antibiotics and timely hemodynamic support that are currently in use. with the accumulation of big data and advancements in data storage techniques, innovative and pragmatic machine learning methods that have entered our lives demonstrate good prediction performance in the medical field. machine learning-based models developed to predict mortality in patients monitored in the intensive care unit are available in the literature and provide an opportunity for earlier intervention in patients. using our own patient data, in the intensive care unit, patients with bloodstream infections, both with and without mortality, will be examined retrospectively in two subgroups for comparison. the investigators aim to predict mortality that can develop in carbapenem-resistant gram-negative bacilli bloodstream infections with a machine learning-based model.

Eligibility criteria:
inclusion criteria: * in our study, patients who were monitored in our hospital's tertiary intensive care unit between june 2017 and june 2023 and developed bloodstream infections with carbapenem-resistant enterobacteriaceae, carbapenem-resistant acinetobacter baumannii and carbapenem-resistant pseudomonas aeruginosa will be retrospectively included. exclusion criteria: * patients under the age of 18 and those with infections other than bloodstream infections will not be included.

Keywords: intensive care unit
relation between prst score, skin conductance and bis

Conditions: Awakeness, Pain

Summary: determine the relation between prst (pressure, rate, sweating, tears) score, skin conductance (sc) and bispectral index (bis) values during anesthesia

probability of \>0 points in the prst as a function of bis and number of fluctuations in mean skin conductance (nfsc) will be recorded during the anesthesia.

Eligibility criteria:
inclusion criteria: * minor elective surgery * general anaesthesia exclusion criteria: * autonomic neuropathy * presence of a pacemaker * medication with anticholinergic drugs * use of ketamine, clonidine
a community pharmacist-led intervention to improve screening of sleep apnea in primary care

Conditions: Sleep Apnea

Summary: the purpose of this study is to evaluate the feasibility and the effectiveness of sleep apnea screening program for patients at risk in community pharmacies.

background: the sleep apnea syndrome (sas) is a common disease but unknown. according to epidemiological studies, approximately 5% to 10% of the general population is living with sas. untreated sleep apnea has an important individual impact: it is accompanied by sleep disturbances and vigilance and frequent co-morbidities such as hypertension, diabetes or other cardiovascular diseases. also, it has a cost to the community due to significant traffic accidents and work accidents more frequent in this population and weight for health insurance for cardiovascular diseases. however, its screening and its management remain largely insufficient. the report of the ministry of health in 2006 estimated that only 15% of subjects with a sas would be diagnosed. the law "hospital, patients, health and territories" (hpst) in 2009 provides pharmacists with new responsibilities in the health screening, care coordination, or in therapeutic education (article 38 of law hpst). objective: in this dual context, this study aims to assess the feasibility and effectiveness of an information campaign and screening of sas in patients at risk in the community pharmacies. the investigators analyze whether the involvement of community pharmacists in the care pathway of a patient at risk is effective, that is to say if it improves the detection rate and diagnostic the disease in this population. project description: 400 patients at risk of sas will be recruited by the participating pharmacists. screening intervention consists in 2 validated questionnaires which evaluate sas risk (berlin questionnaire, epworth sleepiness scale). pharmacist distributes also an information leaflet about sas, and refers patient to general practitioner with questionnaires results. patients are followed by the pharmacists for 6 months.

Eligibility criteria:
inclusion criteria: * taking 1 or more anti-hypertension drugs * overweight (bmi \> 25) * snoring * signed informed consent exclusion criteria: * to have a sleep apnea treatment * not to have a referent doctor * to have a long-term illness * did not sign informed consent

Keywords: sleep apnea screening community pharmacy
mgb/oagb versus rygb after failed sleeve

Conditions: Obesity

Summary: sleeve gastrectomy is the most performed bariatric procedure worldwide. but a growing number of data documents that some patients have to be surgical revised due to weight regain or gastro-esophageal reflux disease. this study elaborates weather roux-en-y gastric bypass (rygb) or mini/one anastomosis gastric bypass (mgb/oagb) is a better second step procedure after failed sleeve gastrectomy.

all patients who underwent rygb or mgb/oagb between october 2014 and december 2016 after failed sleeve gastrectomy will be recorded and analyzed in relation to weight loss, intra- and postoperative complications (clavien-dindo) and postoperative morbidity up to one year follow-up.

Eligibility criteria:
inclusion criteria: patients with failed sleeve due to * weight regain * weight loss failure * gastro-esophageal reflux disease grade b exclusion criteria: -

Keywords: obesity surgery failed sleeve gastrectomy roux-en-y gastric bypass mini/one anastomosis gastric bypass
effect of transfusion of plasma on endothelial during liver transplantation

Conditions: End Stage Liver DIsease; Liver Transplantation

Summary: to study the effects of plasma transfusionon during liver transplantation on endothelial condition and short-term outcome in patients with end-stage liver disease.


Eligibility criteria:
inclusion criteria: * child a/b cirrhosis * patients who undergo the first olt * informed and consented * complete follow-up * cooperate with treatment exclusion criteria: * re-transplant * combined liver and other organ transplantation * bmi≥30kg/m2 * patients with hypertension, diabetes, coronary heart disease, chronic renal insufficiency, preoperative pulmonary infection, pleural effusion * acute liver failure

Keywords: endothelial plasma
concurrent immunotherapy with postoperative radiotherapy in intermediate/high risk hnscc patients unfit for cisplatin: the import study (import)

Conditions: Head and Neck Squamous Cell Carcinoma

Summary: to investigate weather concurrent js001 with postoperative radiotherapy would have survival benefit in intermediate/high risk hnscc patients who cannot take cisplatin


Eligibility criteria:
inclusion criteria: * 1. histologically confirmed squamous cell carcinoma of the head and neck.site of tumor origin in the oral cavity, oropharynx, larynx, hypopharynx , or sinuses (excluding nasopharynx) 2. with at least one risk factors after radical surgery ①positive margin; ②close margin（\<5mm); ③ene;④pni;⑤lvi; ⑤ pt3-4/n2-3( ajcc 8th).⑥ level iv/v lymph node metastases for opc or oc. 3. have at least one contraindication to cisplatin as defined: ① age\>65 years old; ②creatinine clearance (cc) \> 30 and \< 60 cc/min for this calculation, use the cockroft-gault formula: cc = 0.85 (if female)\* ((140-age) / (serum creatinine)) \* (weight in kg / 72); ③ zubrod performance status 2; ④pre-existing peripheral neuropathy grade ≥ 1; ⑤history of hearing loss, defined as either: ▪ existing need of a hearing aid or ≥ 25 decibel shift over 2 contiguous frequencies on a pretreatment hearing test as clinically indicated. 4. no distant metastases 5. no synchronous or concurrent head and neck primary tumors 6. ecog ps 0-2 7. adequate organ function including the following: 1. absolute neutrophil count (anc) \>= 1.5 \* 10\^9/l 2. platelets count \>= 80 \* 10\^9/l 3. hemoglobin \>= 80 g/dl 4. ast and alt \<= 2.5 times institutional upper limit of normal (uln) 5. total bilirubin \<= 1.5 times institutional uln 6. creatinine clearance \>30 ml/min 8. signed written informed consent exclusion criteria: 1. prior chemotherapy or anti-cancer biologic therapy for any type of cancer, or prior radiotherapy to the head and neck region 2. other previous cancer, except for in situ cervical cancer and cutaneous basal cell carcinoma 3. pregnant or breast-feeding females, or females and males of childbearing potential not taking adequate contraceptive measures 4. uncontrolled concomitant illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia 5. active, known or suspected autoimmune disease such as interstitial pneumonia, uveitis, crohn's disease, autoimmune thyroiditis. subjects with cured childhood asthma, type i diabetes mellitus and hypothyroidism only requiring hormone replacement, or skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment 6. using systemic immunosuppressive agents and continue the dose within 2 weeks prior to the enrollment;

Keywords: head and neck cancer radiotherapy pd-1
determination of performance characteristics of the massplex factor ii/v leiden test

Conditions: Factor V Leiden; Factor II; Thrombosis

Summary: to establish the overall agreement of the massplex factor ii and factor v leiden genotyping test with bi-directional dna sequencing for factor ii and factor v leiden.

de-identified banked genomic dna samples derived from whole blood from subjects with suspected thrombophilia will be collected from one or more clinical sites. three clinical laboratory sites will analyze the samples with the fii/fvl test. bi-directional dna sequencing will be performed on all samples at an independent core reference laboratory.

Eligibility criteria:
inclusion criteria: * suspected thrombophilia * 18 years of age or older exclusion criteria: * none
structured patient education and quality of life of elderly patients with diabetes mellitus- a prospective study

Conditions: Impact of Structured DTTP on Quality of Life; Insulin Therapy; Metabolic Control; Psychological Aspects

Summary: the improvement of the quality of life (qol) is one of the key treatment goals in patients with diabetes mellitus. objective: prospective study to evaluate the impact of structured diabetes education on the qol in insulin-treated, elderly patients with type 2 diabetes mellitus. inpatients with insulin treated type 2 diabetes or failure of oral antidiabetic therapy were successively recruited and participated in the structured inpatient diabetes treatment and teaching program (dttp) for insulin therapy qol was assessed before and six months after participation in the dttp with the standardised questionnaire of lohr analysing the subscales: social relations, physical complaints, worries about the future, diet restrictions, fear of hypoglycemia, and daily struggles.

all patients with type 2 diabetes mellitus, who were older than 54 years and admitted by general practitioner to the inpatient unit of the university hospital of jena, germany, for participation in a structured dttp for insulin therapy because of hyperglycemia, were candidates for successive inclusion in the study. all patients participated in a five day inpatient structured dttp for single or split dose administration of intermediate-acting insulin which included instruction in insulin injection, self- monitoring, hypoglycemia, acute/late complications, nutrition and foot care. quality of life was assessed by using a validated instrument, the standardised qol- questionnaire of lohr et al. (21) both before and six months after participation in the dttp. this questionnaire consists of 58 likert- scaled items comprising the subscales: social relations, physical complaints, worries about the future, diet restrictions, fear of hypoglycemia, and daily struggles. higher scores reflect higher quality of life with 100% as an optimum quality of life. the primary outcome measure regarding patients metabolic control was the improvement of quality of life six months after dttp.

Eligibility criteria:
inclusion criteria: * diabetes mellitus, insulin therapy, age \>54 years, hyperglycemia exclusion criteria: * dementia, severe neurological deficits, polioencephalitis, rejection of informed consent
extended support for persons with pituitary tumours after surgery

Conditions: Pituitary Tumor Benign; Surgery

Summary: patients with pituitary tumours often live with life-long consequences of their disease. treatment options include surgery, radiotherapy and medical therapy. symptoms associated with the tumour and/or its treatment affects several areas of life. the year after pituitary surgery constitutes an important time-period with medical evaluations of surgery and decisions on hormonal substitution. the development and evaluation of extended patient support during this time-point is limited. care based on person-centredness has exclusively been promoted which comprises a care where care providers inquire how patients view their health situation and what their needs, resources, and preferences are. person-centredness focuses on preserving patient autonomy, function, and well-being and strives to emphasize patient involvement through equalizing power between health care professionals and the patient with the main goal of an enhanced health situation. the aim of the study is to evaluate if a support within a person-centered care practice one year after surgery increases wellbeing for patients with pituitary tumours.


Eligibility criteria:
inclusion criteria: 1. pituitary tumour; adenoma or craniopharyngioma 2. planned neurosurgery due to pituitary tumour exclusion criteria: 1. pituitary carcinomas 2. health conditions which may restrain the understanding of the study and/or the ability to adhere to the protocol for example decreased cognitive functions or drug addiction.

Keywords: person-centred care clinical pathway intervention quasi-experimental